These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20180619)

  • 1. Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.
    Yang H; Rotstein DM
    Expert Opin Ther Pat; 2010 Mar; 20(3):325-54. PubMed ID: 20180619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of HIV infection with the CCR5 antagonist maraviroc.
    Kromdijk W; Huitema AD; Mulder JW
    Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.
    Singh IP; Chauthe SK
    Expert Opin Ther Pat; 2011 Feb; 21(2):227-69. PubMed ID: 21219250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
    AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
    [No Abstract]   [Full Text] [Related]  

  • 6. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Something new under the sun. Maraviroc poised for approval.
    Huff B
    GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
    [No Abstract]   [Full Text] [Related]  

  • 10. How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
    van Lunzen J
    Eur J Med Res; 2007 Oct; 12(9):435-40. PubMed ID: 17933725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug safety evaluation of maraviroc for the treatment of HIV infection.
    Wasmuth JC; Rockstroh JK; Hardy WD
    Expert Opin Drug Saf; 2012 Jan; 11(1):161-74. PubMed ID: 22118500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM; Rockstroh JK
    Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
    MacArthur RD; Novak RM
    Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New HIV drug classes on the horizon.
    Opar A
    Nat Rev Drug Discov; 2007 Apr; 6(4):258-9. PubMed ID: 17457997
    [No Abstract]   [Full Text] [Related]  

  • 15. Maraviroc first-line therapy for HIV infection. Too risky.
    Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
    Horster S; Goebel FD
    Infection; 2006 Apr; 34(2):110-3. PubMed ID: 16703305
    [No Abstract]   [Full Text] [Related]  

  • 17. Maraviroc: integration of a new antiretroviral drug class into clinical practice.
    Vandekerckhove L; Verhofstede C; Vogelaers D
    J Antimicrob Chemother; 2008 Jun; 61(6):1187-90. PubMed ID: 18400807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Conclusions and perspectives. Maraviroc].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc.
    Fadel H; Temesgen Z
    Drugs Today (Barc); 2007 Nov; 43(11):749-58. PubMed ID: 18174962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.